董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ronald Wooten | 男 | Director | 63 | 未披露 | 未持股 | 2022-12-08 |
| John C. Taylor | 男 | Director, Chief Executive Officer | 52 | 未披露 | 未持股 | 2022-12-08 |
| Michael R. Dougherty | 男 | Director | 64 | 9.77万美元 | 未持股 | 2022-12-08 |
| Cristina Csimma | 女 | Director | 63 | 9.92万美元 | 未持股 | 2022-12-08 |
| Vincent J. Milano | 男 | Chair of the Board | 59 | 133.72万美元 | 未持股 | 2022-12-08 |
| James Arthur Geraghty | 男 | Director | 68 | 11.06万美元 | 未持股 | 2022-12-08 |
| Maxine Gowen | 女 | Director | 64 | 7.91万美元 | 未持股 | 2022-12-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bryant D. Lim | 男 | Chief Business Officer and General Counsel | 51 | 73.18万美元 | 未持股 | 2022-12-08 |
| John C. Taylor | 男 | Director, Chief Executive Officer | 52 | 未披露 | 未持股 | 2022-12-08 |
| Andy Jordan | 男 | Chief Strategy Officer | 75 | 未披露 | 未持股 | 2022-12-08 |
| Carl Kraus | 男 | Chief Medical Officer | 53 | 未披露 | 未持股 | 2022-12-08 |
| Daniel Salain | 男 | Chief Operating Officer | 55 | 未披露 | 未持股 | 2022-12-08 |
| John J. Kirby | 男 | Chief Financial Officer | 50 | 60.56万美元 | 未持股 | 2022-12-08 |
董事简历
中英对照 | 中文 | 英文- Ronald Wooten
-
由于此次收购完成，Ronald Wooten被任命为Idera Pharmaceuticals, Inc.董事会成员。在收购完成之前，Wooten先生自2021年5月起担任Aceragen董事会成员。自2010年成立以来，Wooten先生一直是NovaQuest Capital Management，L.L.C.的合伙人，该公司是一家专注于生物制药领域的投资公司。自2010年以来，Wooten先生担任NovaQuest Pharma Opportunities Fund III、NovaQuest Pharma Opportunities Fund IV、NovaQuest Pharma Opportunities Fund V、NovaQuest Private Equity Fund I和NovaQuest Animal Health Fund I的投资委员会成员。2000年至2010年，他担任合同研究公司（“Quintiles”）旗下NovaQuest业务部门的总裁。伍滕先生之前担任昆泰公司执行副总裁，并于2008年至2010年在昆泰公司董事会任职。Wooten先生以前的经历包括在第一联合证券公司工作了九年，在那里他担任投资银行业务的董事总经理。Wooten先生拥有北卡罗来纳大学教堂山分校的化学学士学位和波士顿大学的工商管理硕士学位。
Ronald Wooten was appointed to Idera Pharmaceuticals, Inc. Board of Directors in connection with the closing of the Acquisition. Prior to the closing of the Acquisition, Mr. Wooten served as a member of the board of directors of Aceragen since May 2021. Mr. Wooten has been a partner of NovaQuest Capital Management, L.L.C., an investment firm that focuses on the biopharmaceutical sector, since its inception in 2010. Since 2010, Mr. Wooten has been a member of the investment committee of NovaQuest Pharma Opportunities Fund III, NovaQuest Pharma Opportunities Fund IV, NovaQuest Pharma Opportunities Fund V, NovaQuest Private Equity Fund I, and NovaQuest Animal Health Fund I. From 2000 to 2010, he was President of the NovaQuest business unit of Quintiles Inc., a contract research company ("Quintiles"). Mr. Wooten was previously Executive Vice President at Quintiles and served on its board of directors from 2008 to 2010. Mr. Wooten's previous experience includes nine years with First Union Securities, where he served as a Managing Director of Investment Banking. Mr. Wooten holds a B.A. degree in Chemistry from the University of North Carolina at Chapel Hill and an M.B.A. from Boston University. - 由于此次收购完成，Ronald Wooten被任命为Idera Pharmaceuticals, Inc.董事会成员。在收购完成之前，Wooten先生自2021年5月起担任Aceragen董事会成员。自2010年成立以来，Wooten先生一直是NovaQuest Capital Management，L.L.C.的合伙人，该公司是一家专注于生物制药领域的投资公司。自2010年以来，Wooten先生担任NovaQuest Pharma Opportunities Fund III、NovaQuest Pharma Opportunities Fund IV、NovaQuest Pharma Opportunities Fund V、NovaQuest Private Equity Fund I和NovaQuest Animal Health Fund I的投资委员会成员。2000年至2010年，他担任合同研究公司（“Quintiles”）旗下NovaQuest业务部门的总裁。伍滕先生之前担任昆泰公司执行副总裁，并于2008年至2010年在昆泰公司董事会任职。Wooten先生以前的经历包括在第一联合证券公司工作了九年，在那里他担任投资银行业务的董事总经理。Wooten先生拥有北卡罗来纳大学教堂山分校的化学学士学位和波士顿大学的工商管理硕士学位。
- Ronald Wooten was appointed to Idera Pharmaceuticals, Inc. Board of Directors in connection with the closing of the Acquisition. Prior to the closing of the Acquisition, Mr. Wooten served as a member of the board of directors of Aceragen since May 2021. Mr. Wooten has been a partner of NovaQuest Capital Management, L.L.C., an investment firm that focuses on the biopharmaceutical sector, since its inception in 2010. Since 2010, Mr. Wooten has been a member of the investment committee of NovaQuest Pharma Opportunities Fund III, NovaQuest Pharma Opportunities Fund IV, NovaQuest Pharma Opportunities Fund V, NovaQuest Private Equity Fund I, and NovaQuest Animal Health Fund I. From 2000 to 2010, he was President of the NovaQuest business unit of Quintiles Inc., a contract research company ("Quintiles"). Mr. Wooten was previously Executive Vice President at Quintiles and served on its board of directors from 2008 to 2010. Mr. Wooten's previous experience includes nine years with First Union Securities, where he served as a Managing Director of Investment Banking. Mr. Wooten holds a B.A. degree in Chemistry from the University of North Carolina at Chapel Hill and an M.B.A. from Boston University.
- John C. Taylor
-
由于此次收购交易的完成，John C. Taylor被任命为Idera Pharmaceuticals, Inc.首席执行官并进入Idera Pharmaceuticals, Inc.董事会。泰勒先生是Aceragen的联合创始人，自2021年成立以来曾担任其首席执行官。自2018年以来，泰勒先生一直担任北卡罗来纳州生物技术中心的驻地企业家。2013年至2018年，Taylor先生担任Spyryx Biosciences，Inc.的首席执行官，该公司专注于开发针对与囊性纤维化相关的肺部并发症的新型ENaC调节疗法。在此之前，Taylor先生于2009年至2013年担任Synageva BioPharma Corp.的企业发展副总裁；于2008年至2009年担任Javelin Pharmaceuticals，Inc.的业务发展副总裁。Taylor先生拥有克莱姆森大学生物科学学士学位和宾夕法尼亚大学技术管理科学硕士学位。
John C. Taylor was appointed as Idera Pharmaceuticals, Inc. Chief Executive Officer and to Idera Pharmaceuticals, Inc. Board of Directors in connection with the closing of the Acquisition. Mr. Taylor was a co-founder and previously served as the Chief Executive Officer of Aceragen since its founding in 2021. Since 2018, Mr. Taylor has served as the Entrepreneur In Residence for the North Carolina Biotechnology Center. From 2013 to 2018, Mr. Taylor served as the Chief Executive Officer for Spyryx Biosciences, Inc., a company focused on developing therapies targeting novel regulation of ENaC for lung complications associated with cystic fibrosis. Prior to this, Mr. Taylor served as the Vice President, Corporate Development for Synageva BioPharma Corp. from 2009 to 2013 and Vice President, Business Development for Javelin Pharmaceuticals, Inc. from 2008 to 2009. Mr. Taylor holds a Bachelor of Science in Biological Sciences from Clemson University and a Master of Science in Technology Management from the University of Pennsylvania. - 由于此次收购交易的完成，John C. Taylor被任命为Idera Pharmaceuticals, Inc.首席执行官并进入Idera Pharmaceuticals, Inc.董事会。泰勒先生是Aceragen的联合创始人，自2021年成立以来曾担任其首席执行官。自2018年以来，泰勒先生一直担任北卡罗来纳州生物技术中心的驻地企业家。2013年至2018年，Taylor先生担任Spyryx Biosciences，Inc.的首席执行官，该公司专注于开发针对与囊性纤维化相关的肺部并发症的新型ENaC调节疗法。在此之前，Taylor先生于2009年至2013年担任Synageva BioPharma Corp.的企业发展副总裁；于2008年至2009年担任Javelin Pharmaceuticals，Inc.的业务发展副总裁。Taylor先生拥有克莱姆森大学生物科学学士学位和宾夕法尼亚大学技术管理科学硕士学位。
- John C. Taylor was appointed as Idera Pharmaceuticals, Inc. Chief Executive Officer and to Idera Pharmaceuticals, Inc. Board of Directors in connection with the closing of the Acquisition. Mr. Taylor was a co-founder and previously served as the Chief Executive Officer of Aceragen since its founding in 2021. Since 2018, Mr. Taylor has served as the Entrepreneur In Residence for the North Carolina Biotechnology Center. From 2013 to 2018, Mr. Taylor served as the Chief Executive Officer for Spyryx Biosciences, Inc., a company focused on developing therapies targeting novel regulation of ENaC for lung complications associated with cystic fibrosis. Prior to this, Mr. Taylor served as the Vice President, Corporate Development for Synageva BioPharma Corp. from 2009 to 2013 and Vice President, Business Development for Javelin Pharmaceuticals, Inc. from 2008 to 2009. Mr. Taylor holds a Bachelor of Science in Biological Sciences from Clemson University and a Master of Science in Technology Management from the University of Pennsylvania.
- Michael R. Dougherty
-
Michael R. Dougherty，他曾一直担任公司董事（2013年5月以来）。从2012年5月到2012年10月，他曾担任Kalidex Pharmaceuticals公司的首席执行官兼董事会成员。他曾担任Adolor公司的总裁兼首席执行官、董事（从2006年12月到2011年12月）。他于2002年11月加入Adolor公司，担任负责商业运营的高级副总裁，并被任命为总裁兼首席执行官，也曾担任多种职务，包括首席运营官兼首席财务官。从2000年11月到2002年11月，他担任Genomics Collaborative公司（一家民营功能基因组学公司）的总裁兼首席运营官。此前，他曾担任Genaera Corporation（一个上市的生物技术公司）的多种高级职务，包括总裁兼首席执行官，也曾担任Centocor公司（上市的生物技术公司）的多种高级职务，包括高级副总裁兼首席财务官。他目前担任Cempra公司（上市公司）、Celator Pharmaceuticals公司（上市公司）、Trevena公司的董事。他也曾担任Viropharma Incorporated公司的董事（从2004年到2014年1月）。他获得Villanova University的经济学学士学位。他广泛了解生物技术产业的关键问题，包括金融、研发、销售和营销、策略和操作，也拥有担任几家生物技术公司的首席执行官的管理经验，因此他应该服务于公司的董事会。
Michael R. Dougherty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2019, and as chair of Idera Pharmaceuticals, Inc. Board of Directors from 2021 until 2022. Mr. Dougherty currently serves on the board of directors of Trevena, Inc. (Nasdaq: TRVN). Mr. Dougherty was executive chairman of Celator Pharmaceuticals, Inc., or Celator, from 2015 until its acquisition by Jazz Pharmaceuticals plc in 2016; he also served as a director of Celator from 2013 to 2016. Mr. Dougherty previously served in a variety of senior positions in the biopharmaceutical industry, including as CEO, President, Chief Operating Officer, and Chief Financial Officer. He also previously served as a member of the board of directors of and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), Foundation Medicine, Inc., Adolor Corporation, Genaera Corporation, Aviragen Therapeutics, Inc., Cempra, Inc., and ViroPharma Incorporated. Mr. Dougherty received a Bachelor of Science in Accounting from Villanova University. - Michael R. Dougherty，他曾一直担任公司董事（2013年5月以来）。从2012年5月到2012年10月，他曾担任Kalidex Pharmaceuticals公司的首席执行官兼董事会成员。他曾担任Adolor公司的总裁兼首席执行官、董事（从2006年12月到2011年12月）。他于2002年11月加入Adolor公司，担任负责商业运营的高级副总裁，并被任命为总裁兼首席执行官，也曾担任多种职务，包括首席运营官兼首席财务官。从2000年11月到2002年11月，他担任Genomics Collaborative公司（一家民营功能基因组学公司）的总裁兼首席运营官。此前，他曾担任Genaera Corporation（一个上市的生物技术公司）的多种高级职务，包括总裁兼首席执行官，也曾担任Centocor公司（上市的生物技术公司）的多种高级职务，包括高级副总裁兼首席财务官。他目前担任Cempra公司（上市公司）、Celator Pharmaceuticals公司（上市公司）、Trevena公司的董事。他也曾担任Viropharma Incorporated公司的董事（从2004年到2014年1月）。他获得Villanova University的经济学学士学位。他广泛了解生物技术产业的关键问题，包括金融、研发、销售和营销、策略和操作，也拥有担任几家生物技术公司的首席执行官的管理经验，因此他应该服务于公司的董事会。
- Michael R. Dougherty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2019, and as chair of Idera Pharmaceuticals, Inc. Board of Directors from 2021 until 2022. Mr. Dougherty currently serves on the board of directors of Trevena, Inc. (Nasdaq: TRVN). Mr. Dougherty was executive chairman of Celator Pharmaceuticals, Inc., or Celator, from 2015 until its acquisition by Jazz Pharmaceuticals plc in 2016; he also served as a director of Celator from 2013 to 2016. Mr. Dougherty previously served in a variety of senior positions in the biopharmaceutical industry, including as CEO, President, Chief Operating Officer, and Chief Financial Officer. He also previously served as a member of the board of directors of and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), Foundation Medicine, Inc., Adolor Corporation, Genaera Corporation, Aviragen Therapeutics, Inc., Cempra, Inc., and ViroPharma Incorporated. Mr. Dougherty received a Bachelor of Science in Accounting from Villanova University.
- Cristina Csimma
-
Cristina Csimma，女，药学博士，自2010年9月起担任本公司董事。自2012年11月起，担任Cydan, Inc.负责罕见疾病治疗的首席执行官。之前在生物制药和投资行业以及政府和患者组织担任战略咨询的角色。2009年1月至2011年5月担任Virdante制药公司负责药物开发的副总裁。从2006年到2008年担任Clarus Ventures有限责任公司（生命科学风险投资）的主管。2001至2006年担任惠氏研究（制药）的 资深总监/董事，负责实验医学和转化研究。2000至2001年担任惠氏研究（制药）负责临床研究和开发的主任。此前担任多个职位，包括1988年至2000年担任遗传学研究所临床研究的副主任，自1983年至1988年于Dana-Farber癌症研究所担任临床药师。持有美国马萨诸塞药学院及联合健康科学学院的药学学士学位和博士学位，并从东北大学获得卫生专业硕士学位。
Cristina Csimma is a biopharmaceutical leader and strategic advisor with decades of experience in biotechnology, large pharma, and venture capital. Dr. Csimma currently serves on the board of directors of Syncona Partners, LLP (LON: SYNC), having been elected to its board of directors in February 2022. She also serves as a board director and a member of the compensation committee of Palisade Bio, Inc. (Nasdaq: PALI), having been elected to its board of directors in 2017. She also serves as the chair of the board of directors of Caraway Therapeutics, Inc. since 2019 (executive chair in 2019). Dr. Csimma also serves on advisory boards, including the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee since 2006; the Harvard and Brigham and Women's Hospital MRCT Center External Advisory Board since 2015; the TREAT-NMD Advisory Committee for Therapeutics (TACT) since 2009; and the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network since 2013.Dr. Csimma previously served as chair of the board of directors of Forendo Pharma between 2020 and 2021 (executive chair in 2021) when it was acquired by Organon & Co. Dr. Csimma also previously served as a director on the boards of Seneca Biopharma, Inc. (Nasdaq: SNCA; formerly Neuralstem Inc., from 2017 until 2021 when it merged with Leading BioSciences Inc. to form Palisade Bio), Juniper Pharmaceuticals, Inc. (from 2010 until its acquisition by Catalent, Inc. in 2018), and Vtesse Inc. (from 2014 until its acquisition by Sucampo Pharmaceuticals, Inc. in 2017). Dr. Csimma was the executive chair and a senior advisor of Exonics Therapeutics, Inc. (from 2016 to 2017), and was President, founding CEO, and board director of Cydan Inc. from 2012 to 2014. She also served on the board of directors of T1D Exchange (non-profit Type 1 Diabetes) from 2018 to 2020 and the NIH Blueprint Neurotherapeutics Network External Oversight Committee from 2014 to 2018, was Vice President of Drug Development at Virdante Pharmaceuticals Inc. from 2009 to 2011, Principal at Clarus Ventures LLC (now Blackstone Life Science), and held roles of increasing responsibility in Clinical Development and Translational Research at Wyeth (now Pfizer Inc.), Genetics Institute, and Dana Farber Cancer Institute. Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University. - Cristina Csimma，女，药学博士，自2010年9月起担任本公司董事。自2012年11月起，担任Cydan, Inc.负责罕见疾病治疗的首席执行官。之前在生物制药和投资行业以及政府和患者组织担任战略咨询的角色。2009年1月至2011年5月担任Virdante制药公司负责药物开发的副总裁。从2006年到2008年担任Clarus Ventures有限责任公司（生命科学风险投资）的主管。2001至2006年担任惠氏研究（制药）的 资深总监/董事，负责实验医学和转化研究。2000至2001年担任惠氏研究（制药）负责临床研究和开发的主任。此前担任多个职位，包括1988年至2000年担任遗传学研究所临床研究的副主任，自1983年至1988年于Dana-Farber癌症研究所担任临床药师。持有美国马萨诸塞药学院及联合健康科学学院的药学学士学位和博士学位，并从东北大学获得卫生专业硕士学位。
- Cristina Csimma is a biopharmaceutical leader and strategic advisor with decades of experience in biotechnology, large pharma, and venture capital. Dr. Csimma currently serves on the board of directors of Syncona Partners, LLP (LON: SYNC), having been elected to its board of directors in February 2022. She also serves as a board director and a member of the compensation committee of Palisade Bio, Inc. (Nasdaq: PALI), having been elected to its board of directors in 2017. She also serves as the chair of the board of directors of Caraway Therapeutics, Inc. since 2019 (executive chair in 2019). Dr. Csimma also serves on advisory boards, including the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee since 2006; the Harvard and Brigham and Women's Hospital MRCT Center External Advisory Board since 2015; the TREAT-NMD Advisory Committee for Therapeutics (TACT) since 2009; and the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network since 2013.Dr. Csimma previously served as chair of the board of directors of Forendo Pharma between 2020 and 2021 (executive chair in 2021) when it was acquired by Organon & Co. Dr. Csimma also previously served as a director on the boards of Seneca Biopharma, Inc. (Nasdaq: SNCA; formerly Neuralstem Inc., from 2017 until 2021 when it merged with Leading BioSciences Inc. to form Palisade Bio), Juniper Pharmaceuticals, Inc. (from 2010 until its acquisition by Catalent, Inc. in 2018), and Vtesse Inc. (from 2014 until its acquisition by Sucampo Pharmaceuticals, Inc. in 2017). Dr. Csimma was the executive chair and a senior advisor of Exonics Therapeutics, Inc. (from 2016 to 2017), and was President, founding CEO, and board director of Cydan Inc. from 2012 to 2014. She also served on the board of directors of T1D Exchange (non-profit Type 1 Diabetes) from 2018 to 2020 and the NIH Blueprint Neurotherapeutics Network External Oversight Committee from 2014 to 2018, was Vice President of Drug Development at Virdante Pharmaceuticals Inc. from 2009 to 2011, Principal at Clarus Ventures LLC (now Blackstone Life Science), and held roles of increasing responsibility in Clinical Development and Translational Research at Wyeth (now Pfizer Inc.), Genetics Institute, and Dana Farber Cancer Institute. Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University.
- Vincent J. Milano
-
Vincent J. Milano，2008年3月至2014年1月，担任ViroPharma Incorporated的总裁、首席执行官；2006年1月至2008年3月，担任其首席运营官；1997年11月至2008年3月，担任其副总裁、首席财务官。之前，他曾担任ViroPharma的财务与管理副总裁、财务总管，以及财务与管理执行总监。加入ViroPharma之前，他任职于独立的会计师事务所KPMG LLP，在1991-1996年间，担任其高级经理。他在Rider College获得会计学士学位。由于他在制药行业的丰富经验、财务和会计方面的丰富知识，以及在其它上市公司董事会的任职经验，所以本公司相信，他有资格担任本公司董事。
Vincent J. Milano is the Chair of Idera Pharmaceuticals, Inc. Board, having previously served as Idera Pharmaceuticals, Inc. President and CEO from 2014 to September 2022 and has been a member of Idera Pharmaceuticals, Inc. Board of Directors since 2014. Prior to joining Idera Pharmaceuticals, Inc. , Mr. Milano served as Chairman, President, and CEO of ViroPharma Incorporated ("ViroPharma"), a pharmaceutical company that was acquired by Shire plc in 2014, from 2008 to 2014, as its Vice President, Chief Financial Officer, and Chief Operating Officer from 2006 to 2008, and as its Vice President, Chief Financial Officer, and Treasurer from 1996 to 2005. Mr. Milano also served on the board of directors of ViroPharma from 2008 to 2014. Prior to joining ViroPharma, Mr. Milano served in increasingly senior roles, most recently senior manager, at KPMG LLP, an independent registered public accounting firm, from 1985 to 1996.Mr. Milano currently serves on the board of directors of Aclaris Therapeutics, Inc. (Nasdaq: ACRS) and Biocryst Pharmaceuticals, Inc. (Nasdaq: BCRX), each a publicly traded company, since 2020 and 2021, respectively. Mr. Milano previously served as a director of Spark Therapeutics, Inc., Vanda Pharmaceuticals Inc., and privately held VenatoRx Pharmaceuticals, Inc. from 2014 to 2019, from 2010 to 2019, and from 2013 to 2022, respectively. Mr. Milano holds a Bachelor of Science degree in Accounting from Rider College. - Vincent J. Milano，2008年3月至2014年1月，担任ViroPharma Incorporated的总裁、首席执行官；2006年1月至2008年3月，担任其首席运营官；1997年11月至2008年3月，担任其副总裁、首席财务官。之前，他曾担任ViroPharma的财务与管理副总裁、财务总管，以及财务与管理执行总监。加入ViroPharma之前，他任职于独立的会计师事务所KPMG LLP，在1991-1996年间，担任其高级经理。他在Rider College获得会计学士学位。由于他在制药行业的丰富经验、财务和会计方面的丰富知识，以及在其它上市公司董事会的任职经验，所以本公司相信，他有资格担任本公司董事。
- Vincent J. Milano is the Chair of Idera Pharmaceuticals, Inc. Board, having previously served as Idera Pharmaceuticals, Inc. President and CEO from 2014 to September 2022 and has been a member of Idera Pharmaceuticals, Inc. Board of Directors since 2014. Prior to joining Idera Pharmaceuticals, Inc. , Mr. Milano served as Chairman, President, and CEO of ViroPharma Incorporated ("ViroPharma"), a pharmaceutical company that was acquired by Shire plc in 2014, from 2008 to 2014, as its Vice President, Chief Financial Officer, and Chief Operating Officer from 2006 to 2008, and as its Vice President, Chief Financial Officer, and Treasurer from 1996 to 2005. Mr. Milano also served on the board of directors of ViroPharma from 2008 to 2014. Prior to joining ViroPharma, Mr. Milano served in increasingly senior roles, most recently senior manager, at KPMG LLP, an independent registered public accounting firm, from 1985 to 1996.Mr. Milano currently serves on the board of directors of Aclaris Therapeutics, Inc. (Nasdaq: ACRS) and Biocryst Pharmaceuticals, Inc. (Nasdaq: BCRX), each a publicly traded company, since 2020 and 2021, respectively. Mr. Milano previously served as a director of Spark Therapeutics, Inc., Vanda Pharmaceuticals Inc., and privately held VenatoRx Pharmaceuticals, Inc. from 2014 to 2019, from 2010 to 2019, and from 2013 to 2022, respectively. Mr. Milano holds a Bachelor of Science degree in Accounting from Rider College.
- James Arthur Geraghty
-
James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。于2018年07月18日获委任为北海康成制药有限公司提名及企业管治委员会委员。于2022年02月16日获委任为北海康成制药有限公司审核委员会委员。
James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc. - James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。于2018年07月18日获委任为北海康成制药有限公司提名及企业管治委员会委员。于2022年02月16日获委任为北海康成制药有限公司审核委员会委员。
- James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc.
- Maxine Gowen
-
Maxine Gowen，自2007年11月创立本公司以来，担任本公司的总裁和首席执行官，以及是本公司的一位董事会成员。在加入本公司之前，她曾是GlaxoSmithKline plc或GSK的外部药物发现卓越中心担任高级副总裁，在15年任期内在GlaxoSmithKline plc担任过各种领导职位。在GSK之前，她曾于2008-2012年期间，是英国（UK）Bath大学骨与关节系骨细胞生物学资深讲师和主任。2008-2012年期间，是一家公共生物医药公司- Human Genome Sciences股份有限公司的一位董事。她是从英国（UK）Sheffield大学获得她的博士学位，从宾夕法尼亚大学（University of Pennsylvania）Wharton学院获得的学术荣誉工商管理硕士学位，以及从英国（UK）Bristol大学获得的生物化学荣誉学士学位。
Maxine Gowen served as the CEO and a board director of TamuroBio Inc., a privately held drug development company, from 2019 to 2021, and she remains on the board of directors. She was the founding President and CEO of Trevena, Inc., or Trevena, (Nasdaq: TRVN), a publicly traded biopharmaceutical company, from 2007 until her retirement in 2018; she remained a member of its board of directors until 2021. Prior to joining Trevena, Dr. Gowen was Senior Vice President for the Center of Excellence for External Drug Discovery at GlaxoSmithKline plc, or GSK, where she held a variety of leadership positions during her tenure of 15 years. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, of the University of Bath, U.K. Dr. Gowen has served as a director of Aclaris Therapeutics, Inc. (Nasdaq: ACRS) since 2019, Passage Bio, Inc. (Nasdaq: PASG), and as its Chairwoman, since 2021, and Merus NV (Nasdaq: MRUS) since 2021, each a publicly traded company. She previously held a board seat in the state biotechnology industry association, Life Sciences of Pennsylvania from 2015 until 2021 and in the national biotechnology industry association, BIO, from 2008 until 2018. Dr. Gowen previously served as a director of Human Genome Sciences, Inc., from 2008 until 2012, and Akebia Therapeutics, Inc. (Nasdaq: AKBA) from 2014 until 2021, both publicly traded companies, as well as Panorama Medicine, from 2020 until 2021, a privately held biotechnology company. She received her Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K. - Maxine Gowen，自2007年11月创立本公司以来，担任本公司的总裁和首席执行官，以及是本公司的一位董事会成员。在加入本公司之前，她曾是GlaxoSmithKline plc或GSK的外部药物发现卓越中心担任高级副总裁，在15年任期内在GlaxoSmithKline plc担任过各种领导职位。在GSK之前，她曾于2008-2012年期间，是英国（UK）Bath大学骨与关节系骨细胞生物学资深讲师和主任。2008-2012年期间，是一家公共生物医药公司- Human Genome Sciences股份有限公司的一位董事。她是从英国（UK）Sheffield大学获得她的博士学位，从宾夕法尼亚大学（University of Pennsylvania）Wharton学院获得的学术荣誉工商管理硕士学位，以及从英国（UK）Bristol大学获得的生物化学荣誉学士学位。
- Maxine Gowen served as the CEO and a board director of TamuroBio Inc., a privately held drug development company, from 2019 to 2021, and she remains on the board of directors. She was the founding President and CEO of Trevena, Inc., or Trevena, (Nasdaq: TRVN), a publicly traded biopharmaceutical company, from 2007 until her retirement in 2018; she remained a member of its board of directors until 2021. Prior to joining Trevena, Dr. Gowen was Senior Vice President for the Center of Excellence for External Drug Discovery at GlaxoSmithKline plc, or GSK, where she held a variety of leadership positions during her tenure of 15 years. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, of the University of Bath, U.K. Dr. Gowen has served as a director of Aclaris Therapeutics, Inc. (Nasdaq: ACRS) since 2019, Passage Bio, Inc. (Nasdaq: PASG), and as its Chairwoman, since 2021, and Merus NV (Nasdaq: MRUS) since 2021, each a publicly traded company. She previously held a board seat in the state biotechnology industry association, Life Sciences of Pennsylvania from 2015 until 2021 and in the national biotechnology industry association, BIO, from 2008 until 2018. Dr. Gowen previously served as a director of Human Genome Sciences, Inc., from 2008 until 2012, and Akebia Therapeutics, Inc. (Nasdaq: AKBA) from 2014 until 2021, both publicly traded companies, as well as Panorama Medicine, from 2020 until 2021, a privately held biotechnology company. She received her Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K.
高管简历
中英对照 | 中文 | 英文- Bryant D. Lim
Bryant D.Lim自2018年9月起担任我们的高级副总裁，总法律顾问兼秘书。在加入我们之前，林先生于2014年3月至2018年9月在因塞特医疗公司担任Vice President，助理总法律顾问，并在此之前担任全球首席合规官。在因塞特医疗公司之前，Lim先生从2009年1月到2014年1月被Shire plc收购，在Viropharma Incorporated担任越来越重要的职务。Lim先生曾担任默克制药公司的助理律师，并与Morgan，Lewis&Bockius，LLP有联系。Lim先生的法律职业生涯始于担任一名联邦法官的法律文员。Lim先生在维拉诺瓦大学法学院（Villanova University School of Law）获得法学博士学位，他目前在该校的附属学院任教，教授药物和生物制剂法。Lim先生在罗切斯特大学（University of Rochester）获得学士学位。Lim先生还任职于宾夕法尼亚州生命科学公司（Life Sciences of Pennsylvania）的董事会。
Bryant D. Lim was appointed as the Chief Business Officer and General Counsel of Idera in connection with the closing of the Acquisition. Mr. Lim previously served as the Senior Vice President, Chief Business Officer and General Counsel of Idera from June 2022 to September 2022, and Senior Vice President from 2018 to June 2022. Prior to joining Idera Pharmaceuticals, Inc. , Mr. Lim served as Vice President, Assistant General Counsel and, prior to that, Global Chief Compliance Officer at Incyte Corporation from 2014 to 2018. Prior to his time at Incyte Corporation, Mr. Lim held roles of increasing responsibility at ViroPharma Incorporated from 2009 until its acquisition by Shire Plc in 2014. Prior to that, Mr. Lim served as Assistant Counsel at Merck & Co., Inc. and was associated with Morgan, Lewis & Bockius, LLP. Mr. Lim began his legal career as a law clerk for a federal judge. Mr. Lim received his J.D. from Villanova University School of Law, where he served on its adjunct faculty teaching about the Law of Drugs and Biologics. Mr. Lim received his B.A. from the University of Rochester. Mr. Lim has served on the board of directors of the state biotechnology industry association, Life Sciences of Pennsylvania, since 2019.- Bryant D.Lim自2018年9月起担任我们的高级副总裁，总法律顾问兼秘书。在加入我们之前，林先生于2014年3月至2018年9月在因塞特医疗公司担任Vice President，助理总法律顾问，并在此之前担任全球首席合规官。在因塞特医疗公司之前，Lim先生从2009年1月到2014年1月被Shire plc收购，在Viropharma Incorporated担任越来越重要的职务。Lim先生曾担任默克制药公司的助理律师，并与Morgan，Lewis&Bockius，LLP有联系。Lim先生的法律职业生涯始于担任一名联邦法官的法律文员。Lim先生在维拉诺瓦大学法学院（Villanova University School of Law）获得法学博士学位，他目前在该校的附属学院任教，教授药物和生物制剂法。Lim先生在罗切斯特大学（University of Rochester）获得学士学位。Lim先生还任职于宾夕法尼亚州生命科学公司（Life Sciences of Pennsylvania）的董事会。
- Bryant D. Lim was appointed as the Chief Business Officer and General Counsel of Idera in connection with the closing of the Acquisition. Mr. Lim previously served as the Senior Vice President, Chief Business Officer and General Counsel of Idera from June 2022 to September 2022, and Senior Vice President from 2018 to June 2022. Prior to joining Idera Pharmaceuticals, Inc. , Mr. Lim served as Vice President, Assistant General Counsel and, prior to that, Global Chief Compliance Officer at Incyte Corporation from 2014 to 2018. Prior to his time at Incyte Corporation, Mr. Lim held roles of increasing responsibility at ViroPharma Incorporated from 2009 until its acquisition by Shire Plc in 2014. Prior to that, Mr. Lim served as Assistant Counsel at Merck & Co., Inc. and was associated with Morgan, Lewis & Bockius, LLP. Mr. Lim began his legal career as a law clerk for a federal judge. Mr. Lim received his J.D. from Villanova University School of Law, where he served on its adjunct faculty teaching about the Law of Drugs and Biologics. Mr. Lim received his B.A. from the University of Rochester. Mr. Lim has served on the board of directors of the state biotechnology industry association, Life Sciences of Pennsylvania, since 2019.
- John C. Taylor
由于此次收购交易的完成，John C. Taylor被任命为Idera Pharmaceuticals, Inc.首席执行官并进入Idera Pharmaceuticals, Inc.董事会。泰勒先生是Aceragen的联合创始人，自2021年成立以来曾担任其首席执行官。自2018年以来，泰勒先生一直担任北卡罗来纳州生物技术中心的驻地企业家。2013年至2018年，Taylor先生担任Spyryx Biosciences，Inc.的首席执行官，该公司专注于开发针对与囊性纤维化相关的肺部并发症的新型ENaC调节疗法。在此之前，Taylor先生于2009年至2013年担任Synageva BioPharma Corp.的企业发展副总裁；于2008年至2009年担任Javelin Pharmaceuticals，Inc.的业务发展副总裁。Taylor先生拥有克莱姆森大学生物科学学士学位和宾夕法尼亚大学技术管理科学硕士学位。
John C. Taylor was appointed as Idera Pharmaceuticals, Inc. Chief Executive Officer and to Idera Pharmaceuticals, Inc. Board of Directors in connection with the closing of the Acquisition. Mr. Taylor was a co-founder and previously served as the Chief Executive Officer of Aceragen since its founding in 2021. Since 2018, Mr. Taylor has served as the Entrepreneur In Residence for the North Carolina Biotechnology Center. From 2013 to 2018, Mr. Taylor served as the Chief Executive Officer for Spyryx Biosciences, Inc., a company focused on developing therapies targeting novel regulation of ENaC for lung complications associated with cystic fibrosis. Prior to this, Mr. Taylor served as the Vice President, Corporate Development for Synageva BioPharma Corp. from 2009 to 2013 and Vice President, Business Development for Javelin Pharmaceuticals, Inc. from 2008 to 2009. Mr. Taylor holds a Bachelor of Science in Biological Sciences from Clemson University and a Master of Science in Technology Management from the University of Pennsylvania.- 由于此次收购交易的完成，John C. Taylor被任命为Idera Pharmaceuticals, Inc.首席执行官并进入Idera Pharmaceuticals, Inc.董事会。泰勒先生是Aceragen的联合创始人，自2021年成立以来曾担任其首席执行官。自2018年以来，泰勒先生一直担任北卡罗来纳州生物技术中心的驻地企业家。2013年至2018年，Taylor先生担任Spyryx Biosciences，Inc.的首席执行官，该公司专注于开发针对与囊性纤维化相关的肺部并发症的新型ENaC调节疗法。在此之前，Taylor先生于2009年至2013年担任Synageva BioPharma Corp.的企业发展副总裁；于2008年至2009年担任Javelin Pharmaceuticals，Inc.的业务发展副总裁。Taylor先生拥有克莱姆森大学生物科学学士学位和宾夕法尼亚大学技术管理科学硕士学位。
- John C. Taylor was appointed as Idera Pharmaceuticals, Inc. Chief Executive Officer and to Idera Pharmaceuticals, Inc. Board of Directors in connection with the closing of the Acquisition. Mr. Taylor was a co-founder and previously served as the Chief Executive Officer of Aceragen since its founding in 2021. Since 2018, Mr. Taylor has served as the Entrepreneur In Residence for the North Carolina Biotechnology Center. From 2013 to 2018, Mr. Taylor served as the Chief Executive Officer for Spyryx Biosciences, Inc., a company focused on developing therapies targeting novel regulation of ENaC for lung complications associated with cystic fibrosis. Prior to this, Mr. Taylor served as the Vice President, Corporate Development for Synageva BioPharma Corp. from 2009 to 2013 and Vice President, Business Development for Javelin Pharmaceuticals, Inc. from 2008 to 2009. Mr. Taylor holds a Bachelor of Science in Biological Sciences from Clemson University and a Master of Science in Technology Management from the University of Pennsylvania.
- Andy Jordan
Andy Jordan被任命为Idera的首席战略干事，负责完成收购工作。此前，Jordan先生于2021年至2022年9月担任Aceragen的Chief Financial Officer。在加入Aceragen之前，Jordan先生创立了AR Jordan Consulting，主要与生物技术公司合作，专注于将治疗孤儿/罕见病的药物推向市场，并于2008年至2021年担任其负责人。在此之前，Jordan先生曾在Guildford Pharmaceuticals，Inc.、Odyssey Pharmaceuticals，Inc.和InfraReDx，Inc.担任高管职位。Jordan先生曾于2003年至2011年担任Gemin X BioPharmaceuticals，Inc.董事会成员，并于2013年至2018年担任Spyryx Biosciences，Inc.董事会成员。Jordan先生拥有罗格斯大学的文学士学位和罗格斯大学——纽瓦克分校的专业会计工商管理硕士学位。
Andy Jordan was appointed as the Chief Strategy Officer of Idera in connection with the closing of the Acquisition. Previously, Mr. Jordan served as the Chief Financial Officer of Aceragen from 2021 to September 2022. Prior to joining Aceragen, Mr. Jordan founded AR Jordan Consulting, working primarily with biotechnology companies, focusing on bringing to market drugs to treat orphan/rare diseases, serving as its principal from 2008 to 2021. Prior to this, Mr. Jordan held executive-level positions with Guildford Pharmaceuticals, Inc., Odyssey Pharmaceuticals, Inc., and InfraReDx, Inc. Mr. Jordan served as a member of the board of directors for Gemin X BioPharmaceuticals, Inc. from 2003 to 2011 and Spyryx Biosciences,Inc. from 2013 to 2018. Mr. Jordan holds a Bachelor of Arts in Liberal Arts from Rutgers University and an M.B.A. in Professional Accounting from Rutgers University—Newark.- Andy Jordan被任命为Idera的首席战略干事，负责完成收购工作。此前，Jordan先生于2021年至2022年9月担任Aceragen的Chief Financial Officer。在加入Aceragen之前，Jordan先生创立了AR Jordan Consulting，主要与生物技术公司合作，专注于将治疗孤儿/罕见病的药物推向市场，并于2008年至2021年担任其负责人。在此之前，Jordan先生曾在Guildford Pharmaceuticals，Inc.、Odyssey Pharmaceuticals，Inc.和InfraReDx，Inc.担任高管职位。Jordan先生曾于2003年至2011年担任Gemin X BioPharmaceuticals，Inc.董事会成员，并于2013年至2018年担任Spyryx Biosciences，Inc.董事会成员。Jordan先生拥有罗格斯大学的文学士学位和罗格斯大学——纽瓦克分校的专业会计工商管理硕士学位。
- Andy Jordan was appointed as the Chief Strategy Officer of Idera in connection with the closing of the Acquisition. Previously, Mr. Jordan served as the Chief Financial Officer of Aceragen from 2021 to September 2022. Prior to joining Aceragen, Mr. Jordan founded AR Jordan Consulting, working primarily with biotechnology companies, focusing on bringing to market drugs to treat orphan/rare diseases, serving as its principal from 2008 to 2021. Prior to this, Mr. Jordan held executive-level positions with Guildford Pharmaceuticals, Inc., Odyssey Pharmaceuticals, Inc., and InfraReDx, Inc. Mr. Jordan served as a member of the board of directors for Gemin X BioPharmaceuticals, Inc. from 2003 to 2011 and Spyryx Biosciences,Inc. from 2013 to 2018. Mr. Jordan holds a Bachelor of Arts in Liberal Arts from Rutgers University and an M.B.A. in Professional Accounting from Rutgers University—Newark.
- Carl Kraus
卡尔·克劳斯被任命为Idera的首席医疗官，与收购交易的完成有关。在此任命之前，Kraus博士于2021年至2022年9月担任Aceragen的首席医疗官。在此之前的2017年，Kraus博士创立了Arrevus，Inc.（“Arrevus”），这是一家临床阶段的生物技术公司，为孤儿疾病开发新疗法，并于2017年至2020年担任首席执行官。在创立Arrevus之前，Kraus博士于2013年至2017年担任Nanotherapeutics，Inc.的首席医疗官，于2010年至2013年担任Medscape，LLC的医疗事务、风险管理/REMS 副总裁，并于2008年至2010年担任PRA国际科学事务的传染病副总裁。在加入该行业之前，Kraus博士曾于2002年至2005年在食品和药物管理局的药物评价和研究中心担任医务官员。克劳斯博士拥有圣路易斯华盛顿大学生物学学士学位，并在圣路易斯华盛顿大学医学院获得医学博士学位。
Carl Kraus was appointed as the Chief Medical Officer of Idera in connection with the closing of the Acquisition. Prior to this appointment, Dr. Kraus served as the Chief Medical Officer of Aceragen from 2021 to September 2022. Prior to this, in 2017, Dr. Kraus founded Arrevus, Inc. ("Arrevus"), a clinical-stage biotechnology company developing novel therapies for orphan diseases, and served as its Chief Executive Officer from 2017 to 2020. Prior to founding Arrevus, Dr. Kraus served as the Chief Medical Officer of Nanotherapeutics, Inc. from 2013 to 2017, the Vice President, Medical Affairs, Risk Management/REMS of Medscape, LLC from 2010 to 2013, and the Vice President, Infectious Diseases, Scientific Affairs of PRA International from 2008 to 2010. Prior to joining industry, Dr. Kraus was a medical officer in the Center for Drug Evaluation and Research at the Food & Drug Administration from 2002 to 2005. Dr. Kraus holds a Bachelor of Arts in Biology from Washington University in St. Louis, and received his M.D. in Medicine from Washington University School of Medicine in St. Louis.- 卡尔·克劳斯被任命为Idera的首席医疗官，与收购交易的完成有关。在此任命之前，Kraus博士于2021年至2022年9月担任Aceragen的首席医疗官。在此之前的2017年，Kraus博士创立了Arrevus，Inc.（“Arrevus”），这是一家临床阶段的生物技术公司，为孤儿疾病开发新疗法，并于2017年至2020年担任首席执行官。在创立Arrevus之前，Kraus博士于2013年至2017年担任Nanotherapeutics，Inc.的首席医疗官，于2010年至2013年担任Medscape，LLC的医疗事务、风险管理/REMS 副总裁，并于2008年至2010年担任PRA国际科学事务的传染病副总裁。在加入该行业之前，Kraus博士曾于2002年至2005年在食品和药物管理局的药物评价和研究中心担任医务官员。克劳斯博士拥有圣路易斯华盛顿大学生物学学士学位，并在圣路易斯华盛顿大学医学院获得医学博士学位。
- Carl Kraus was appointed as the Chief Medical Officer of Idera in connection with the closing of the Acquisition. Prior to this appointment, Dr. Kraus served as the Chief Medical Officer of Aceragen from 2021 to September 2022. Prior to this, in 2017, Dr. Kraus founded Arrevus, Inc. ("Arrevus"), a clinical-stage biotechnology company developing novel therapies for orphan diseases, and served as its Chief Executive Officer from 2017 to 2020. Prior to founding Arrevus, Dr. Kraus served as the Chief Medical Officer of Nanotherapeutics, Inc. from 2013 to 2017, the Vice President, Medical Affairs, Risk Management/REMS of Medscape, LLC from 2010 to 2013, and the Vice President, Infectious Diseases, Scientific Affairs of PRA International from 2008 to 2010. Prior to joining industry, Dr. Kraus was a medical officer in the Center for Drug Evaluation and Research at the Food & Drug Administration from 2002 to 2005. Dr. Kraus holds a Bachelor of Arts in Biology from Washington University in St. Louis, and received his M.D. in Medicine from Washington University School of Medicine in St. Louis.
- Daniel Salain
由于收购完成，Daniel Salain被任命为Idera的首席运营官。在此任命之前，Salain先生于2020年至2022年9月担任Aceragen的首席运营官。2017年至2020年，Salain先生担任Graybug Vision, Inc.的首席运营官，Graybug Vision, Inc.是一家临床阶段的生物制药公司，专注于开发治疗眼部疾病的药物，2015年至2017年担任Ophthotech高级副总裁兼制造与供应链全球主管，Ophthotech是一家临床阶段的生物技术公司。在加入Ophthotech公司之前，Salain先生于1999年至2014年在Aptalis制药公司担任全球运营、制造与供应链副总裁，该公司专注于开发治疗胃肠道疾病的产品。Salain先生拥有印第安纳波利斯大学化学和市场营销理学学士学位。
Daniel Salain was appointed as the Chief Operating Officer of Idera in connection with the closing of the Acquisition. Prior to this appointment, Mr. Salain served as Chief Operating Officer of Aceragen from 2020 to September 2022. Previously, Mr. Salain was the Chief Operating Officer of Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing medicines for ocular diseases, from 2017 to 2020, and was the Senior Vice President, Global Head of Manufacturing & Supply Chain at Ophthotech, a clinical-stage biotechnology company, from 2015 to 2017. Prior to working at Ophthotech, Mr. Salain was the Vice President of Global Operations, Manufacturing & Supply Chain at Aptalis Pharmaceuticals Inc., a company that focused on developing products to treat gastrointestinal diseases and disorders, from 1999 to 2014. Mr. Salain has a Bachelor of Science degree in Chemistry and Marketing from the University of Indianapolis.- 由于收购完成，Daniel Salain被任命为Idera的首席运营官。在此任命之前，Salain先生于2020年至2022年9月担任Aceragen的首席运营官。2017年至2020年，Salain先生担任Graybug Vision, Inc.的首席运营官，Graybug Vision, Inc.是一家临床阶段的生物制药公司，专注于开发治疗眼部疾病的药物，2015年至2017年担任Ophthotech高级副总裁兼制造与供应链全球主管，Ophthotech是一家临床阶段的生物技术公司。在加入Ophthotech公司之前，Salain先生于1999年至2014年在Aptalis制药公司担任全球运营、制造与供应链副总裁，该公司专注于开发治疗胃肠道疾病的产品。Salain先生拥有印第安纳波利斯大学化学和市场营销理学学士学位。
- Daniel Salain was appointed as the Chief Operating Officer of Idera in connection with the closing of the Acquisition. Prior to this appointment, Mr. Salain served as Chief Operating Officer of Aceragen from 2020 to September 2022. Previously, Mr. Salain was the Chief Operating Officer of Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing medicines for ocular diseases, from 2017 to 2020, and was the Senior Vice President, Global Head of Manufacturing & Supply Chain at Ophthotech, a clinical-stage biotechnology company, from 2015 to 2017. Prior to working at Ophthotech, Mr. Salain was the Vice President of Global Operations, Manufacturing & Supply Chain at Aptalis Pharmaceuticals Inc., a company that focused on developing products to treat gastrointestinal diseases and disorders, from 1999 to 2014. Mr. Salain has a Bachelor of Science degree in Chemistry and Marketing from the University of Indianapolis.
- John J. Kirby
JohnJ.Kirby于2015年加入公司，担任公司会计Vice President，并于2018年7月至2019年7月担任财务Vice President，自2019年7月起担任高级副总裁兼首席财务官首席财务官自2018年10月起担任首席会计官。在加入我们之前，Kirby先生于2014年11月至2015年10月担任Endo Pharmaceuticals，Inc.的助理财务总监。2012年8月至2014年7月，Kirby先生担任Viropharma Incorporated的Vice President、首席会计官和公司财务总监，该公司于2014年1月被Shire plc收购。Kirby先生的职业生涯始于毕马威会计师事务所（KPMG，LLP）的梦百合和生命科学实践，并在加入Viropharma Incorporated之前担任阿斯利康制药公司（AstraZeneca Pharmaceuticals L.P.）的区域审计总监。Kirby先生在维拉诺瓦大学（Villanova University）获得会计学学士学位，是宾夕法尼亚州联邦的注册会计师。
John J. Kirby has served as the Chief Financial Officer of Idera since 2019. Mr. Kirby joined the Company in 2015 as Idera Pharmaceuticals, Inc. Vice President of Corporate Accounting. He served as Vice President of Finance from 2018 to 2019 and has served as Senior Vice President and Chief Financial Officer since 2019 (and as principal financial officer and principal accounting officer since 2018). Prior to joining Idera Pharmaceuticals, Inc. , Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals, Inc. from 2014 to 2015. From 2012 to 2014, Mr. Kirby served as Vice President, Chief Accounting Officer and Corporate Controller at ViroPharma Incorporated, which was acquired by Shire Plc in 2014. Mr. Kirby began his career at KPMG, LLP in its Healthcare and Life Science Practice and served as a Regional Audit Director at AstraZeneca Pharmaceuticals L.P. prior to joining ViroPharma Incorporated. Mr. Kirby received his B.S. in Accountancy from Villanova University and is a licensed certified public accountant in the Commonwealth of Pennsylvania. Mr. Kirby has also served on the board of trustees of the Delaware Museum of Nature & Science (formerly the Delaware Museum of Natural History) since 2018.- JohnJ.Kirby于2015年加入公司，担任公司会计Vice President，并于2018年7月至2019年7月担任财务Vice President，自2019年7月起担任高级副总裁兼首席财务官首席财务官自2018年10月起担任首席会计官。在加入我们之前，Kirby先生于2014年11月至2015年10月担任Endo Pharmaceuticals，Inc.的助理财务总监。2012年8月至2014年7月，Kirby先生担任Viropharma Incorporated的Vice President、首席会计官和公司财务总监，该公司于2014年1月被Shire plc收购。Kirby先生的职业生涯始于毕马威会计师事务所（KPMG，LLP）的梦百合和生命科学实践，并在加入Viropharma Incorporated之前担任阿斯利康制药公司（AstraZeneca Pharmaceuticals L.P.）的区域审计总监。Kirby先生在维拉诺瓦大学（Villanova University）获得会计学学士学位，是宾夕法尼亚州联邦的注册会计师。
- John J. Kirby has served as the Chief Financial Officer of Idera since 2019. Mr. Kirby joined the Company in 2015 as Idera Pharmaceuticals, Inc. Vice President of Corporate Accounting. He served as Vice President of Finance from 2018 to 2019 and has served as Senior Vice President and Chief Financial Officer since 2019 (and as principal financial officer and principal accounting officer since 2018). Prior to joining Idera Pharmaceuticals, Inc. , Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals, Inc. from 2014 to 2015. From 2012 to 2014, Mr. Kirby served as Vice President, Chief Accounting Officer and Corporate Controller at ViroPharma Incorporated, which was acquired by Shire Plc in 2014. Mr. Kirby began his career at KPMG, LLP in its Healthcare and Life Science Practice and served as a Regional Audit Director at AstraZeneca Pharmaceuticals L.P. prior to joining ViroPharma Incorporated. Mr. Kirby received his B.S. in Accountancy from Villanova University and is a licensed certified public accountant in the Commonwealth of Pennsylvania. Mr. Kirby has also served on the board of trustees of the Delaware Museum of Nature & Science (formerly the Delaware Museum of Natural History) since 2018.